ClinicalTrials.gg
CompletedNCT07906756CPII-PCOS-IUpdated Oct 30, 2026

The Effectiveness of CPII for Infertility Induced by PCOS in China

An interventional study of Standard Treatment for PCOS-Induced Infertility and Counselling-Integrated Standard Care for PCOS-Induced Infertility in Infertility and Poly Cystic Ovary Syndrome, sponsored by Universiti Sains Malaysia. Completed at 4 sites in China. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Universiti Sains Malaysia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled May 2025, registered Feb 2026).
Updated Oct 30, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
192
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age and is associated with metabolic, reproductive and mental health complications. Its prevalence has been reported to be between 5% and 15% in different studies, showcasing its significant impact on the reproductive health of Chinese women. A holistic approach to PCOS treatment that integrates physical, emotional, and mental health is lacking in China. The integration of counseling and personalized care into existing healthcare frameworks may have economic implications on patients with PCOS-induced infertility.

This study aimed to compare the effectiveness of the counselling, personalized care, and counseling-personalized care-integrated interventions versus the current module on the clinical outcomes over six months among patients of PCOS-induced infertility. The primary outcomes are menstrual cycle, hormonal parameters, metabolic parameters, and biochemical pregnancy. The secondary outcomes include anxiety and depression, sleep quality, and patient satisfaction. This study also explored the perceived challenges and barriers among patients with PCOS-induced infertility and healthcare providers involved in counseling-personalized care-integrated interventions in China.

The mixed-method sequential interpretative design was applied. The quantitative component involved a non-randomized controlled trial. A total of 192 patients were recruited by convenient sampling from reproductive medicine centers of four hospitals in Shandong Province. One hospital implemented each module. Data has been collected through a review of medical records and questionnaires. Descriptive statistical and repeated measure analysis of variance has been applied using SPSS version 28.0. The qualitative component involved the phenomenological approach of in-depth interviews of patients and healthcare providers involved in the counseling-personalized care-integrated interventions. Approximately 36 respondents were invited for online interviews via purposive sampling. A thematic analysis has been performed using Nvivo version 14.

Read the detailed description

The following documents have been approved for use in the study.

1. Research Proposal

In addition to the above mentioned documents, the following technical documents were included in the review on which this approval was based:

  1. Patient Information Sheet and Consent Form (English version) - Phase 1
  2. Patient Information Sheet and Consent Form (Malay version) - Phase 1
  3. Patient Information Sheet and Consent Form (English version) - Phase 2
  4. Patient Information Sheet and Consent Form (Malay version) - Phase 2
  5. Participant Information Sheet and Consent Form (English version) - Phase 2
  6. Participant Information Sheet and Consent Form (Malay version) - Phase 2
  7. Case Report Form
  8. Scoring system for SAS
  9. Scoring system for SDS
  10. Scoring system for SRSS
  11. Scoring system for SWLS
  12. Scoring system for PSQ-18
  13. Interview outline for patients
  14. Interview outline for health care providers
02

Conditions studied

  • Infertility
  • Poly Cystic Ovary Syndrome

Browse trials for

03

In context

Infertility

2,085 studies on the registry are indexed under Infertility; 357 are open to participants now.

This study's enrollment of 192 is above the median of 135 across 1,412 interventional studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Universiti Sains Malaysia is the lead sponsor of 177 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Women of reproductive age with PCOS-induced infertility in the four above-mentioned hospitals, with the following inclusion, exclusion, and withdrawal criteria:

Inclusion Criteria:

  • Confirmed PCOS diagnosis by a physician per Rotterdam standards (antral follicle count (AFC) ≥12, or ovarian volume ≥10 ml; latest update raises AFC threshold to 20 follicles); significant metabolic risks include higher incidence of abnormal blood glucose and metabolic syndrome (Kim et al., 2020).
  • Documented infertility (failure to conceive after 12 months of regular attempts).
  • Aged 18-45 years (PCOS is most common in this group, where women are in a crucial pregnancy-planning stage with important physical and psychological development; extreme ages may cause greater fertility differences).

Exclusion Criteria:

  • Other infertility causes (fallopian tube obstruction, male factor infertility), severe comorbidities, or systemic diseases.
  • Severe or uncontrolled systemic diseases (cardiovascular, renal, liver diseases, or uncontrolled diabetes).
  • Gynecological conditions (endometriosis, untreated thyroid disorders, or significant hormonal imbalances).
  • Prior specific infertility treatments (e.g., in vitro fertilization (IVF), ovulation induction).
  • Obesity or underweight.
  • Simultaneous participation in other clinical trials/studies.
  • Current pregnancy.
  • Severe psychiatric disorders or cognitive impairments.
  • Taking non-PCOS-related medications (hormonal treatments, hypoglycemic, antihypertensive, anti-anxiety, or antidepressant drugs).

Withdrawal Criteria:

  • Ineligibility or failure to meet criteria.
  • Non-compliance with treatment protocol.
  • Serious adverse effects or health risks.
  • Personal reasons or inability to continue.
  • Pregnancy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
192 participants (actual)

Study arms

  • Active comparator
    Standard Treatment Intervention (STI)

    Participants receive standard clinical treatment for PCOS-induced infertility following Chinese clinical guidelines. Interventions include lifestyle management, routine medication guidance, laparoscopic ovarian puncture (for eligible patients), and traditional Chinese medicine care (acupuncture, cupping, moxibustion). No additional psychological counselling or personalized care is provided.

    Behavioral: Standard Treatment for PCOS-Induced Infertility

  • Experimental
    Counselling-Integrated Intervention Arm for PCOS-Induced Infertility

    This arm is based on the standard treatment (same as STI arm) and adds structured psychological counseling. Interventions include cathartic therapy, cognitive behavioral reconstruction, relaxation training, and positive reinforcement for patients with elevated SAS/SDS scores, provided by professional mental health personnel.

    Behavioral: Standard Treatment for PCOS-Induced Infertility · Behavioral: Counselling-Integrated Standard Care for PCOS-Induced Infertility

  • Experimental
    Personalized Care-Integrated Intervention (PII)

    Participants receive the same standard treatment as the STI group plus individualized personalized care, including tailored diet plans, exercise prescription and regular follow-up.

    Behavioral: Standard Treatment for PCOS-Induced Infertility · Behavioral: Personalized Care-Integrated Intervention (PII)

  • Experimental
    Counseling and personalized care-integrated intervention (CPII)

    Participants receive the same standard treatment as the STI group, combined with both psychological counselling and individualized personalized care.

    Behavioral: Standard Treatment for PCOS-Induced Infertility · Behavioral: Integrated Counselling & Personalized Care for PCOS-Induced Infertility

Interventions

  • BehavioralStandard Treatment for PCOS-Induced Infertility

    Standard clinical care for women with PCOS-related infertility following Chinese clinical guidelines. It includes lifestyle guidance, hormone-regulating medication, laparoscopic ovarian puncture for eligible patients, and traditional Chinese medicine care (acupuncture, cupping, moxibustion).

  • BehavioralCounselling-Integrated Standard Care for PCOS-Induced Infertility

    Structured psychological counselling, stress management training and emotional support for infertile women with PCOS, delivered by trained reproductive nursing staff.

  • BehavioralPersonalized Care-Integrated Intervention (PII)

    Individualized care plan based on patients' metabolic status, menstrual characteristics and fertility goals, including tailored diet prescription, personalized exercise scheme and regular follow-up.

  • BehavioralIntegrated Counselling & Personalized Care for PCOS-Induced Infertility

    Integrated intervention combining structured psychological counselling and individualized personalized care, simultaneously addressing psychological distress and self-management of metabolic and reproductive health.

06

What researchers measure

Primary outcomes

  1. Biochemical pregnancy rate

    The proportion of participants with biochemical pregnancy. Biochemical pregnancy is defined as a positive serum β-hCG result above the institutional reference threshold for pregnancy.

    Time frame: 6 months after the start of intervention

  2. Menstrual cycle regularity

    Proportion of participants with regular menstrual cycles, defined as cycle length between 21 and 35 days. Cycle length is calculated from the first day of one menstruation to the first day of the subsequent menstruation.

    Time frame: 6 months after the start of intervention

  3. Serum testosterone level

    Serum testosterone level detected by standard biochemical laboratory assay.

    Time frame: 6 months after the start of intervention

  4. Serum estradiol level

    Serum estradiol level detected by standard biochemical laboratory assay.

    Time frame: 6 months after the start of intervention

  5. Serum progesterone level

    Serum progesterone level detected by standard biochemical laboratory assay.

    Time frame: 6 months after the start of intervention

  6. Serum luteinizing hormone (LH) level

    Serum luteinizing hormone level detected by standard biochemical laboratory assay.

    Time frame: 6 months after the start of intervention

  7. Serum follicle-stimulating hormone (FSH) level

    Serum follicle-stimulating hormone concentration detected by standard biochemical laboratory assay.

    Time frame: 6 months after the start of intervention

  8. Body mass index (BMI)

    Body mass index (BMI, unit: kg/m²), calculated as weight in kilograms divided by height in meters squared.

    Time frame: 6 months after the start of intervention

Secondary outcomes

  1. Anxiety score assessed by Self-Rating Anxiety Scale (SAS)

    Anxiety is assessed by the validated Chinese version of the Self-Rating Anxiety Scale (SAS); higher scores indicate more severe anxiety symptoms.

    Time frame: 6 months after the start of intervention

  2. Depression score measured by Self-Rating Depression Scale (SDS)

    Depression is assessed by the validated Chinese version of the Self-Rating Depression Scale (SDS); higher scores indicate more severe depressive symptoms.

    Time frame: 6 months after the start of intervention

  3. Sleep quality score measured by Self-Rating Scale of Sleep (SRSS)

    Sleep quality is assessed by the Chinese Self-Rating Scale of Sleep (SRSS), a validated 10-item self-report scale; higher total scores indicate worse sleep disturbance.

    Time frame: 6 months after the start of intervention

  4. Life satisfaction score measured by Satisfaction with Life Scale (SWLS)

    Subjective life satisfaction is evaluated using the validated Satisfaction with Life Scale (SWLS); higher scores reflect greater life satisfaction.

    Time frame: 6 months after the start of intervention

  5. Patient satisfaction score measured by Short-form Patient Satisfaction Questionnaire (PSQ-18)

    Patient satisfaction is assessed using the Chinese adapted version of PSQ-18; higher scores represent higher satisfaction with healthcare services.

    Time frame: 6 months after the start of intervention

Other outcomes

  1. To explore the challenges and barriers faced by the patients undergoing counselling personalized care integrated intervention.

    Phase 2 qualitative study. Phenomenological in-depth semi-structured interviews will be conducted among PCOS-induced infertility patients. Data will be transcribed verbatim and analysed via thematic analysis (Braun \& Clarke framework) assisted by NVivo 15.

    Time frame: At the completion of the 6-month intervention

  2. To explore the challenges and barriers faced by the healthcare providers who provide counselling-personalized care integrated intervention to the studied patients.Focuse onGynecologists, counselors and therapists.

    Phase 2 qualitative study. Phenomenological in-depth semi-structured interviews will be conducted among PCOS-induced infertility patients. Data will be transcribed verbatim and analysed via thematic analysis (Braun \& Clarke framework) assisted by NVivo 15.

    Time frame: At the completion of the 6-month intervention

  3. Themes of challenges and barriers from focus group discussions among healthcare providers

    Phase 2 qualitative study. Focus group discussions will be performed among healthcare providers delivering counselling-personalized care integrated intervention. Data will be transcribed verbatim and analysed via thematic analysis (Braun \& Clarke framework) assisted by NVivo 15.

    Time frame: At the completion of the 6-month intervention

07

Study locations

4 sites
  • The Gynecology Department , Qilu Hospital of Shandong University
    Jinan, Shandong 250000, China
  • Reproductive Medicine Department, Jining Medical College Affiliated Hospital
    Jining, Shandong 272000, China
  • Taibai Lake Hospital of the Affiliated Hospital ofJining Medical College
    Jining, Shandong 272000, China
  • The Gynecology Department ,Tengzhou Central People's Hospital
    Tengzhou, Shandong 277500, China
08

References and documents

Individual participant data

Plan to share: Undecided — This study will NOT share individual participant data (IPD). The dataset contains sensitive reproductive, medical and psychological information from women with PCOS-related infertility. Restriction of IPD sharing is approved by JEPeM-USM ethics committee and consistent with the Declaration of Helsinki, GCP, local privacy regulations and the signed informed consent. The study protocol does not include an IPD-sharing plan to prevent unauthorised access and misuse of participants' sensitive health information. Aggregated study results will be presented in publications.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in May 2026, 11 months.

Of 385 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 11 months is below that.

Counting every sponsor, half of 416 studies reached it within 24 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Oct 30, 2026
StartActual
May 11, 2025
Primary completionActual
May 10, 2026
CompletionActual
May 11, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07906756
Responsible party
Yang Sanhui (Investigator (Specialisation: Maternal & Child Health, Community Health Development), Department of Family Medicine, School of Medical Sciences, Universiti Sains Malaysia, Universiti Sains Malaysia) — Principal investigator
First posted
Oct 30, 2026
Start date
May 11, 2025
Primary completion
May 10, 2026
Completion
May 11, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion